# US 2022/0008513 A1 · Combined treatment of primary central nervous system lymphoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008513 A1
- Document ID: US20220008513A1
- Status: Published application
- Kind: A1
- Application number: 17/297,794
- Filed: 2019-12-02
- Published: 2022-01-13
- Earliest claimed: 2018-11-30
- Assignees: Fondazione Centro San Raffaele
- Applicants: Fondazione Centro San Raffaele
- Inventors: Angelo CORTI; Andrés José Maria FERRERI
- Web page: https://patentgrep.com/patent/US20220008513A1

## CPC

- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/53: Hinge
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention refers to the combination of an R-CHOP therapy with an administration of NGR-hTNF or an analog thereof for the treatment of primary central nervous system lymphoma, preferably relapsed/refractory primary central nervous system lymphoma.

## Claims

### Claim 1

A method for the treatment of primary central nervous system lymphoma in a subject, comprising administering a combination of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and NGR-hTNF or an analog thereof
wherein the combination comprises at least one course of R-CHOP preceded by an administration of NGR-hTNF or an analog thereof.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the course of R-CHOP consists of 375 mg/m2 of rituximab, 750 mg/m2 of cyclophosphamide, 50 mg/m2 of doxorubicin and 1.4 mg/m2 of vincristine.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the administration of NGR-hTNF or of an analog thereof is performed before CHOP drugs.

### Claim 4 (depends on 1)

The method according to any one of previous claim 1 wherein the NGR-hTNF administration consists of 0.8 ug/m2.

### Claim 5 (depends on 1)

The method according to claim 1 comprising six courses of R-CHOP each preceded by an administration of NGR-hTNF or an analog thereof.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the courses of R-CHOP preceded by an administration of NGR-hTNF or an analog thereof are separated by 18 to 21 days.

### Claim 7 (depends on 1)

The method according to claim 1 wherein primary central nervous system lymphoma relapsed or is a refractory primary central nervous system lymphoma.
